Familial Partial Lipodystrophy Latest Advances

Genetic dyslipidemias.

Journal: Annales d'endocrinologie

Published: March 22, 2026

Lipodystrophies in Clinical Practice: A Case Series From a Local Health Unit in Portugal.

Journal: Cureus

Published: February 17, 2026

A Novel PPARG R212W Variant Causes Familial Partial Lipodystrophy Type 3: Clinical Presentation and Functional Characterization.

Journal: International journal of molecular sciences

Published: January 15, 2026

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in LMNA.

Journal: International journal of molecular sciences

Published: December 18, 2025

Lamin A/C in health, laminopathies, and familial partial lipodystrophy 2.

Journal: Trends in endocrinology and metabolism: TEM

Published: December 01, 2025

A simple and robust reporter-based framework for deep functional characterization of PPARγ mutants.

Journal: Endocrinology

Published: November 17, 2025

Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

Journal: International journal of molecular sciences

Published: November 17, 2025

Erratum. Gain of Function NOTCH3 Variants Cause Familial Partial Lipodystrophy Due to Activation of Senescence Pathways. Diabetes 2025;74:427-438.

Journal: Diabetes

Published: October 28, 2025

Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum.

Journal: Frontiers in endocrinology

Published: October 15, 2025

Epicardial adipose tissue measurement is an interesting biomarker for cardiovascular health in a case control study of patients with familial partial type 2 lipodystrophy.

Journal: Diabetes & metabolism

Published: October 07, 2025

Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to a Pathogenic LMNA Variant R482: Maternal Transmission to Non-Identical Twins.

Journal: The application of clinical genetics

Published: September 26, 2025

Increased epicardial adipose tissue is part of the phenotype of LMNA-associated partial lipodystrophy and could contribute to increased cardiovascular risk.

Journal: Diabetes & metabolism

Published: September 16, 2025

Familial Partial Lipodystrophy Latest Advances

Find the Latest Research About Familial Partial Lipodystrophy

Genetic dyslipidemias.

Genetic dyslipidemias.

Lipodystrophies in Clinical Practice: A Case Series From a Local Health Unit in Portugal.

Lipodystrophies in Clinical Practice: A Case Series From a Local Health Unit in Portugal.

A Novel PPARG R212W Variant Causes Familial Partial Lipodystrophy Type 3: Clinical Presentation and Functional Characterization.

A Novel PPARG R212W Variant Causes Familial Partial Lipodystrophy Type 3: Clinical Presentation and Functional Characterization.

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in LMNA.

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in LMNA.

Lamin A/C in health, laminopathies, and familial partial lipodystrophy 2.

Lamin A/C in health, laminopathies, and familial partial lipodystrophy 2.

A simple and robust reporter-based framework for deep functional characterization of PPARγ mutants.

A simple and robust reporter-based framework for deep functional characterization of PPARγ mutants.

Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

Erratum. Gain of Function NOTCH3 Variants Cause Familial Partial Lipodystrophy Due to Activation of Senescence Pathways. Diabetes 2025;74:427-438.

Erratum. Gain of Function NOTCH3 Variants Cause Familial Partial Lipodystrophy Due to Activation of Senescence Pathways. Diabetes 2025;74:427-438.

Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum.

Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum.

Epicardial adipose tissue measurement is an interesting biomarker for cardiovascular health in a case control study of patients with familial partial type 2 lipodystrophy.

Epicardial adipose tissue measurement is an interesting biomarker for cardiovascular health in a case control study of patients with familial partial type 2 lipodystrophy.

Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to a Pathogenic LMNA Variant R482: Maternal Transmission to Non-Identical Twins.

Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to a Pathogenic LMNA Variant R482: Maternal Transmission to Non-Identical Twins.

Increased epicardial adipose tissue is part of the phenotype of LMNA-associated partial lipodystrophy and could contribute to increased cardiovascular risk.

Increased epicardial adipose tissue is part of the phenotype of LMNA-associated partial lipodystrophy and could contribute to increased cardiovascular risk.